CTXR Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill - Mentions: GSIT IBIO NERV ADAP ...

These stocks that are showing activity before the opening bell on Tuesday.

11 days ago - By: Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

11 days ago - By: Benzinga - Mentions: EXK SVM PAAS PCAR ...

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

11 days ago - By: Benzinga - Mentions: IVA HBIO IBIO NERV ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

15 days ago - By: Citius Pharmaceuticals, Inc. - Mentions: CTOR

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

16 days ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

2 months ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

2 months ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

3 months ago - By: The Motley Fool

Citius Posts Wider Loss in Fiscal Q3

3 months ago - By: Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Announces Closing of $9.0 Million Public Offering

4 months ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Announces Pricing of $9.0 Million Public Offering

4 months ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

4 months ago - By: Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

5 months ago - By: Citius Oncology, Inc. - Mentions: CTOR

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

5 months ago - By: Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

5 months ago - By: Citius Pharmaceuticals, Inc.

CITIUS PHARMACEUTICALS INC (CTXR) Stock News

CTXR Latest News, Press Relases and Analysis

These stocks that are showing activity before the opening bell on Tuesday.

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Citius Posts Wider Loss in Fiscal Q3

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Announces Closing of $9.0 Million Public Offering

Citius Oncology Announces Pricing of $9.0 Million Public Offering

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules